a 63162 has been researched along with 1-(5-isoquinolinesulfonyl)-2-methylpiperazine in 1 studies
| Studies (a 63162) | Trials (a 63162) | Recent Studies (post-2010) (a 63162) | Studies (1-(5-isoquinolinesulfonyl)-2-methylpiperazine) | Trials (1-(5-isoquinolinesulfonyl)-2-methylpiperazine) | Recent Studies (post-2010) (1-(5-isoquinolinesulfonyl)-2-methylpiperazine) |
|---|---|---|---|---|---|
| 31 | 0 | 0 | 3,412 | 41 | 631 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atluru, D; Atluru, S; Erickson, HH; McVey, DS; Olsen, SC | 1 |
1 other study(ies) available for a 63162 and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
| Article | Year |
|---|---|
Inhibition of equine mononuclear cell proliferation and leukotriene B4 synthesis by a specific 5-lipoxygenase inhibitor, A-63162.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetamides; Animals; Calcimycin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Horses; Indomethacin; Interleukin-2; Isoquinolines; Leukocytes, Mononuclear; Leukotriene B4; Lipoxygenase Inhibitors; Lymphocyte Activation; Phenyl Ethers; Phytohemagglutinins; Piperazines; Protein Kinase Inhibitors | 1992 |